242 related articles for article (PubMed ID: 17299523)
1. Inhibition of the mammalian target of rapamycin impedes lymphangiogenesis.
Huber S; Bruns CJ; Schmid G; Hermann PC; Conrad C; Niess H; Huss R; Graeb C; Jauch KW; Heeschen C; Guba M
Kidney Int; 2007 Apr; 71(8):771-7. PubMed ID: 17299523
[TBL] [Abstract][Full Text] [Related]
2. Rapamycin, a specific inhibitor of the mammalian target of rapamycin, suppresses lymphangiogenesis and lymphatic metastasis.
Kobayashi S; Kishimoto T; Kamata S; Otsuka M; Miyazaki M; Ishikura H
Cancer Sci; 2007 May; 98(5):726-33. PubMed ID: 17425689
[TBL] [Abstract][Full Text] [Related]
3. Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model.
Lang SA; Gaumann A; Koehl GE; Seidel U; Bataille F; Klein D; Ellis LM; Bolder U; Hofstaedter F; Schlitt HJ; Geissler EK; Stoeltzing O
Int J Cancer; 2007 Apr; 120(8):1803-10. PubMed ID: 17230506
[TBL] [Abstract][Full Text] [Related]
4. Inhibitory effect of rapamycin on corneal neovascularization in vitro and in vivo.
Kwon YS; Hong HS; Kim JC; Shin JS; Son Y
Invest Ophthalmol Vis Sci; 2005 Feb; 46(2):454-60. PubMed ID: 15671269
[TBL] [Abstract][Full Text] [Related]
5. 15(S)-hydroxyeicosatetraenoic acid induces angiogenesis via activation of PI3K-Akt-mTOR-S6K1 signaling.
Zhang B; Cao H; Rao GN
Cancer Res; 2005 Aug; 65(16):7283-91. PubMed ID: 16103079
[TBL] [Abstract][Full Text] [Related]
6. Phosphorylation of Akt and ERK1/2 is required for VEGF-A/VEGFR2-induced proliferation and migration of lymphatic endothelium.
Dellinger MT; Brekken RA
PLoS One; 2011; 6(12):e28947. PubMed ID: 22174934
[TBL] [Abstract][Full Text] [Related]
7. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis.
Heckman CA; Holopainen T; Wirzenius M; Keskitalo S; Jeltsch M; Ylä-Herttuala S; Wedge SR; Jürgensmeier JM; Alitalo K
Cancer Res; 2008 Jun; 68(12):4754-62. PubMed ID: 18559522
[TBL] [Abstract][Full Text] [Related]
8. mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor.
Lane HA; Wood JM; McSheehy PM; Allegrini PR; Boulay A; Brueggen J; Littlewood-Evans A; Maira SM; Martiny-Baron G; Schnell CR; Sini P; O'Reilly T
Clin Cancer Res; 2009 Mar; 15(5):1612-22. PubMed ID: 19223496
[TBL] [Abstract][Full Text] [Related]
9. Curcumin inhibits lymphangiogenesis in vitro and in vivo.
Wang W; Sukamtoh E; Xiao H; Zhang G
Mol Nutr Food Res; 2015 Dec; 59(12):2345-54. PubMed ID: 26375757
[TBL] [Abstract][Full Text] [Related]
10. In human endothelial cells rapamycin causes mTORC2 inhibition and impairs cell viability and function.
Barilli A; Visigalli R; Sala R; Gazzola GC; Parolari A; Tremoli E; Bonomini S; Simon A; Closs EI; Dall'Asta V; Bussolati O
Cardiovasc Res; 2008 Jun; 78(3):563-71. PubMed ID: 18250144
[TBL] [Abstract][Full Text] [Related]
11. Dual inhibition of PI3Kalpha and mTOR as an alternative treatment for Kaposi's sarcoma.
Chaisuparat R; Hu J; Jham BC; Knight ZA; Shokat KM; Montaner S
Cancer Res; 2008 Oct; 68(20):8361-8. PubMed ID: 18922908
[TBL] [Abstract][Full Text] [Related]
12. Biochemical monitoring of mTOR inhibitor-based immunosuppression following kidney transplantation: a novel approach for tailored immunosuppressive therapy.
Hartmann B; Schmid G; Graeb C; Bruns CJ; Fischereder M; Jauch KW; Heeschen C; Guba M
Kidney Int; 2005 Dec; 68(6):2593-8. PubMed ID: 16316335
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.
deGraffenried LA; Friedrichs WE; Russell DH; Donzis EJ; Middleton AK; Silva JM; Roth RA; Hidalgo M
Clin Cancer Res; 2004 Dec; 10(23):8059-67. PubMed ID: 15585641
[TBL] [Abstract][Full Text] [Related]
14. Transcriptional profiling of VEGF-A and VEGF-C target genes in lymphatic endothelium reveals endothelial-specific molecule-1 as a novel mediator of lymphangiogenesis.
Shin JW; Huggenberger R; Detmar M
Blood; 2008 Sep; 112(6):2318-26. PubMed ID: 18614759
[TBL] [Abstract][Full Text] [Related]
15. Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis.
Bock F; Onderka J; Dietrich T; Bachmann B; Kruse FE; Paschke M; Zahn G; Cursiefen C
Invest Ophthalmol Vis Sci; 2007 Jun; 48(6):2545-52. PubMed ID: 17525183
[TBL] [Abstract][Full Text] [Related]
16. Everolimus inhibits glomerular endothelial cell proliferation and VEGF, but not long-term recovery in experimental thrombotic microangiopathy.
Keller K; Daniel C; Schöcklmann H; Endlich KH; Kerjaschki D; Johnson RJ; Hugo C
Nephrol Dial Transplant; 2006 Oct; 21(10):2724-35. PubMed ID: 16861242
[TBL] [Abstract][Full Text] [Related]
17. Rapamycin inhibition of the Akt/mTOR pathway blocks select stages of VEGF-A164-driven angiogenesis, in part by blocking S6Kinase.
Xue Q; Nagy JA; Manseau EJ; Phung TL; Dvorak HF; Benjamin LE
Arterioscler Thromb Vasc Biol; 2009 Aug; 29(8):1172-8. PubMed ID: 19443844
[TBL] [Abstract][Full Text] [Related]
18. Rapamycin reverses NPM-ALK-induced glucocorticoid resistance in lymphoid tumor cells by inhibiting mTOR signaling pathway, enhancing G1 cell cycle arrest and apoptosis.
Gu L; Gao J; Li Q; Zhu YP; Jia CS; Fu RY; Chen Y; Liao QK; Ma Z
Leukemia; 2008 Nov; 22(11):2091-6. PubMed ID: 18685609
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD).
Wahl PR; Serra AL; Le Hir M; Molle KD; Hall MN; Wüthrich RP
Nephrol Dial Transplant; 2006 Mar; 21(3):598-604. PubMed ID: 16221708
[TBL] [Abstract][Full Text] [Related]
20. LY303511 (2-piperazinyl-8-phenyl-4H-1-benzopyran-4-one) acts via phosphatidylinositol 3-kinase-independent pathways to inhibit cell proliferation via mammalian target of rapamycin (mTOR)- and non-mTOR-dependent mechanisms.
Kristof AS; Pacheco-Rodriguez G; Schremmer B; Moss J
J Pharmacol Exp Ther; 2005 Sep; 314(3):1134-43. PubMed ID: 15923340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
